| 11.055 -0.735 (-6.23%) | 01-08 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 14.14 | 1-year : | 16.52 |
| Resists | First : | 12.1 | Second : | 14.14 |
| Pivot price | 9.12 |
|||
| Supports | First : | 9.75 | Second : | 8.3 |
| MAs | MA(5) : | 10.07 |
MA(20) : | 9.12 |
| MA(100) : | 8.24 |
MA(250) : | 5.27 |
|
| MACD | MACD : | 0.3 |
Signal : | 0 |
| %K %D | K(14,3) : | 80.2 |
D(3) : | 65.5 |
| RSI | RSI(14): 67.5  |
|||
| 52-week | High : | 12.1 | Low : | 1.02 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ TNGX ] has closed Bollinger Bands are 86.8% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 1 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 11.77 - 11.84 | 11.84 - 11.89 |
| Low: | 10.4 - 10.46 | 10.46 - 10.51 |
| Close: | 10.94 - 11.06 | 11.06 - 11.16 |
Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops Ubiquitin-specific protease 1, an inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. Tango Therapeutics, Inc. has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. The company was founded in 2017 and is based in Cambridge, Massachusetts.
Thu, 08 Jan 2026
Tango Therapeutics appoints new CEO amid leadership transition - TipRanks
Thu, 08 Jan 2026
Cancer drug developer Tango brings in new leader as trials advance - Stock Titan
Thu, 08 Jan 2026
Tango Therapeutics Announces CEO Transition: Barbara Weber to Retire, Malte Peters Appointed Successor - GlobeNewswire
Wed, 07 Jan 2026
Tango Therapeutics stock hits 52-week high at $11.21 By Investing.com - Investing.com Australia
Mon, 05 Jan 2026
Tango Therapeutics appoints Sung Lee to board of directors By Investing.com - Investing.com Canada
Mon, 05 Jan 2026
Biotech finance veteran joins cancer drug developer's board - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 135 (M) |
| Shares Float | 80 (M) |
| Held by Insiders | 4.9 (%) |
| Held by Institutions | 97.4 (%) |
| Shares Short | 33,550 (K) |
| Shares Short P.Month | 30,820 (K) |
| EPS | -0.92 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.42 |
| Profit Margin | -151.2 % |
| Operating Margin | 26.1 % |
| Return on Assets (ttm) | -24.6 % |
| Return on Equity (ttm) | -51.7 % |
| Qtrly Rev. Growth | 363.6 % |
| Gross Profit (p.s.) | -0.51 |
| Sales Per Share | 0.49 |
| EBITDA (p.s.) | -0.81 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -146 (M) |
| Levered Free Cash Flow | -62 (M) |
| PE Ratio | -12.15 |
| PEG Ratio | 0 |
| Price to Book value | 7.73 |
| Price to Sales | 22.38 |
| Price to Cash Flow | -10.22 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|